<p>Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma</p>
Lucy Swift(Alberta Children's Hospital), Aru Narendran(University of Calgary)
Cited by 12
Related Papers
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)
|Pediatric Blood & Cancer|2017|73
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
|Clinical Epigenetics|2017|45